These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 18240167)

  • 1. Sevelamer hydrochloride: a novel treatment of hyperphosphatemia associated with tumor lysis syndrome in children.
    Abdullah S; Diezi M; Sung L; Dupuis LL; Geary D; Abla O
    Pediatr Blood Cancer; 2008 Jul; 51(1):59-61. PubMed ID: 18240167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sevelamer Hydrochloride for Tumor Lysis Syndrome-related Hyperphosphatemia.
    Prasada H
    Indian Pediatr; 2015 Jul; 52(7):613-5. PubMed ID: 26244958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The use of sevelamer in the treatment of resistant hyperphosphataemia in children with chronic renal disease].
    Runowski D; Jachimiak B; Cieślak-Puchalska A; Pacanowska B; Zimoń T
    Pol Merkur Lekarski; 2009 Apr; 26(154):318-21. PubMed ID: 19580197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of efficacy of the phosphate binders nicotinic acid and sevelamer hydrochloride in hemodialysis patients.
    Ahmadi F; Shamekhi F; Lessan-Pezeshki M; Khatami MR
    Saudi J Kidney Dis Transpl; 2012 Sep; 23(5):934-8. PubMed ID: 22982903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sevelamer hydrochloride improves hyperphosphatemia in hemodialysis patients with low bone turnover rate and low intact parathyroid hormone levels.
    Kokuho T; Toya Y; Kawaguchi Y; Tamura K; Iwatsubo K; Dobashi Y; Nakazawa A; Takeda H; Iwatsubo M; Hirawa N; Yasuda G; Ohnishi T; Umemura S
    Ther Apher Dial; 2007 Dec; 11(6):442-8. PubMed ID: 18028171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized controlled trial of bixalomer versus sevelamer hydrochloride in hemodialysis patients with hyperphosphatemia.
    Akizawa T; Origasa H; Kameoka C; Kaneko Y; Kawasaki S;
    Ther Apher Dial; 2014 Apr; 18(2):122-31. PubMed ID: 24720402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of gastric acid suppression with pantoprazole on the efficacy of sevelamer hydrochloride as a phosphate binder in haemodialysis patients: a pilot study.
    Lai B; Cervelli MJ
    Nephrology (Carlton); 2012 May; 17(4):402-6. PubMed ID: 22329674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The influence of short-term magnesium carbonate treatment on calcium-phosphorus balance in dialysis patients].
    Zwiech R; Dryja P; Łacina D; Króliczak V; Chrul S; Kacprzyk F
    Wiad Lek; 2011; 64(1):9-14. PubMed ID: 21812357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis.
    Itoh K; Tanaka M; Hashiguchi J; Funakoshi S; Nakano H; Kubo H; Kono T; Uchino J; Masaki K; Date T; Shigematsu T;
    Ther Apher Dial; 2008 Apr; 12(2):126-32. PubMed ID: 18387160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sevelamer hydrochloride in peritoneal dialysis patients: results of a multicenter cross-sectional study.
    Ramos R; Moreso F; Borras M; Ponz E; Buades JM; Teixidó J; Morey A; Garcia C; Vera M; Doñate MT; de Arellano MR; Barbosa F; González MT
    Perit Dial Int; 2007; 27(6):697-701. PubMed ID: 17984434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sevelamer is cost-saving vs. calcium carbonate in non-dialysis-dependent CKD patients in italy: a patient-level cost-effectiveness analysis of the INDEPENDENT study.
    Ruggeri M; Cipriani F; Bellasi A; Russo D; Di Iorio B
    Blood Purif; 2014; 37(4):316-24. PubMed ID: 25171148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients.
    Tonelli M; Wiebe N; Culleton B; Lee H; Klarenbach S; Shrive F; Manns B;
    Nephrol Dial Transplant; 2007 Oct; 22(10):2856-66. PubMed ID: 17906326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of hyperphosphatemia is related with the reduction of C-reactive protein in dialysis patients. Study in sevelamer-resistant dialysis patients treated with chitosan chewing gum as salivary phosphate binder.
    Calò LA; Savica V; Piccoli A; Fusaro M; D'Angelo A; Davis PA
    Ren Fail; 2011; 33(1):11-4. PubMed ID: 21219199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sevelamer carbonate.
    Barna MM; Kapoian T; O'Mara NB
    Ann Pharmacother; 2010 Jan; 44(1):127-34. PubMed ID: 19955298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis.
    Yokoyama K; Akiba T; Fukagawa M; Nakayama M; Sawada K; Kumagai Y; Chertow GM; Hirakata H
    Nephrol Dial Transplant; 2014 May; 29(5):1053-60. PubMed ID: 24376274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of SBR759, a novel calcium-free, iron(III)-based phosphate binder, in Asian patients undergoing hemodialysis: A 12-week, randomized, open-label, dose-titration study versus sevelamer hydrochloride.
    Chen JB; Chiang SS; Chen HC; Obayashi S; Nagasawa M; Hexham JM; Balfour A; Junge G; Akiba T; Fukagawa M
    Nephrology (Carlton); 2011 Nov; 16(8):743-50. PubMed ID: 21854503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sevelamer treatment strategy in peritoneal dialysis patients: conventional dose does not make best use of resources.
    Chow KM; Szeto CC; Kwan BC; Leung CB; Li PK
    J Nephrol; 2007; 20(6):674-82. PubMed ID: 18046669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients.
    Shaheen FA; Akeel NM; Badawi LS; Souqiyyeh MZ
    Saudi Med J; 2004 Jun; 25(6):785-91. PubMed ID: 15195212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Phosphate binders in chronic kidney disease: the positions of sevelamer].
    Fomin VV; Shilov EM; Svistunov AA; Milovanov IuS
    Ter Arkh; 2013; 85(6):96-9. PubMed ID: 23875200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does concomitant administration of sevelamer and calcium carbonate modify the control of phosphatemia?
    Ouellet G; Cardinal H; Mailhot M; Ste-Marie LG; Roy L
    Ther Apher Dial; 2010 Apr; 14(2):172-7. PubMed ID: 20438539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.